-
Clinical proteomics platform
We use the latest technology in proteomics to discover, validate and exploit biomarkers involved in several human diseases.
We use the latest technology in proteomics to discover, validate and exploit biomarkers involved in several human diseases.
We are specialists in preparing your samples for analysis, using various techniques.
Contact us for more information and prices.
We use the latest generation of LCMS for protein quantification : Hepcidin, Orexin and ApoE phenotyping (contact us for other analytes)
Starting from 10 Euros per run.
We offer identification and characterization of major proteins in a complex sample.
160 Euros per LC-MS/MS run (lasting 1 hour).
We always use the latest technologies (SIMOA, MSD) to perform highly sensitive assays.
Contact us for prices.
Founded in 2008, the Clinical Proteomics Platform aims to provide medical, biological and technical services to academic and industrial teams. Our laboratory hosts various analysis techniques, allowing us to treat a high volume of samples. High quality pre-analytical and preparation steps are essential for proper analysis, we value these steps and are specialists in sample pre-fractionation. The platform plays a major role in clinical research at the University Hospital of Montpellier, ranked 7th in the national SIGAPS ranking (number of publications) and in the top 6 French university hospitals in research.
SIMOA, Quanterix
In competition with Luminex, the Meso Scale Discovery MULTI-ARRAY detects biomarkers such as cytokines in simplex or multiplex. The biomarkers are measured with the latest generation of electroluminescence methods.
A list of products can be found on this site.
Quickplex SQ120, Meso Scale Discovery
In competition with Luminex, the Meso Scale Discovery MULTI-ARRAY detects biomarkers such as cytokines in simplex or multiplex. The biomarkers are being measured with the latest generation of electroluminescence methods.
A list of products can be found on this site.
The MRM method (Multiple Reaction Monitoring) is a mass spectrometry technique that is widespread in the clinical field to perform targeted quantification of several analytes of interest and several small molecules.
The development of MRM methods can be done on different types of matrices from biological fluids (whole blood, urine) to cell cultures
The technique of high resolution mass spectrometry allows the identification and characterisation of a large number of proteins in complex mixtures.
The new Impact II ™ is the latest innovation of Bruker Daltonics mass spectrometry products. This is part of the "Ultra-high-resolution Qq-Time-Of-Flight” technique which can reach a resolution of >50,000 (FSR). This brings new perspectives to the large-scaled identification of proteins in complex biological samples, thanks to the high level of analytical performance offered by Impact II ™.
